Skip to main
IOVA
IOVA logo

Iovance Biotherapeutics (IOVA) Stock Forecast & Price Target

Iovance Biotherapeutics (IOVA) Analyst Ratings

Based on 16 analyst ratings
Buy
Strong Buy 44%
Buy 38%
Hold 19%
Sell 0%
Strong Sell 0%

Bulls say

Iovance Biotherapeutics Inc. is poised for significant growth, underscored by its projected revenue for FY25, which is expected to range between $450 million and $475 million, fueled by increased demand and strategic efforts to enhance community referrals. The company's recent quarterly revenue results demonstrated a robust year-over-year increase, with 4Q24 revenue reaching $73.7 million, reflecting a strong performance in Amtagvi and Proleukin products. Moreover, with management forecasting gross product margins to exceed 70% in the coming years and a cash burn projected to remain under $300 million in 2025, Iovance is well-positioned to capitalize on its therapeutic advancements and market presence in the oncology space.

Bears say

Iovance Biotherapeutics Inc. faces a challenging financial outlook primarily due to higher-than-anticipated cash burn rates and difficulties in securing necessary capital for product launches and achieving commercial profitability. Projections for revenue growth appear dim, as reported earnings indicate a potential miss in 2025, alongside concerns about regulatory approvals beyond post-checkpoint melanoma that could further strain financial estimates. Additionally, potential setbacks related to clinical efficacy in various cancer types and the company's history of manufacturing challenges could lead to downward revisions of projections and greater financial instability.

Iovance Biotherapeutics (IOVA) has been analyzed by 16 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 38% recommend Buy, 19% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Iovance Biotherapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Iovance Biotherapeutics (IOVA) Forecast

Analysts have given Iovance Biotherapeutics (IOVA) a Buy based on their latest research and market trends.

According to 16 analysts, Iovance Biotherapeutics (IOVA) has a Buy consensus rating as of Aug 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.34, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.34, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Iovance Biotherapeutics (IOVA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.